Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Account Payables (2016 - 2025)

Assembly Biosciences has reported Change in Account Payables over the past 11 years, most recently at -$512000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at -$512000.0 for Q4 2025, up 31.73% from a year ago — trailing twelve months through Dec 2025 was $586000.0 (up 372.58% YoY), and the annual figure for FY2025 was $586000.0, up 372.58%.
  • Change in Account Payables for Q4 2025 was -$512000.0 at Assembly Biosciences, down from $940000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for ASMB hit a ceiling of $1.0 million in Q2 2022 and a floor of -$1.3 million in Q1 2023.
  • Median Change in Account Payables over the past 5 years was -$192000.0 (2021), compared with a mean of -$171350.0.
  • Biggest five-year swings in Change in Account Payables: plummeted 586.71% in 2021 and later soared 1677.42% in 2022.
  • Assembly Biosciences' Change in Account Payables stood at $31000.0 in 2021, then soared by 1677.42% to $551000.0 in 2022, then tumbled by 153.9% to -$297000.0 in 2023, then tumbled by 152.53% to -$750000.0 in 2024, then soared by 31.73% to -$512000.0 in 2025.
  • The last three reported values for Change in Account Payables were -$512000.0 (Q4 2025), $940000.0 (Q3 2025), and -$132000.0 (Q2 2025) per Business Quant data.